RNA interference therapeutics for cancer: Challenges and opportunities (Review)

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 9-15

  Bora, Roop Singh ^a   Gupta, Dikshi ^a,c   Mukkur, Trilochan Kanwaljit Singh ^b   Saini, Kulvinder Singh ^a,d  

^a RANBAXY LABORATORIES LTD   (India)

^b CURTIN UNIVERSITY   (Australia)

^c INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^d ETERNAL UNIVERSITY   (India)

Author keywords

Cancer; Gene silencing; RNA interference; Short interfering RNA; Short interfering RNA delivery; Target specificity

Indexed keywords

ALN VSP02; ATU 027; CALAA 01; CYCLODEXTRIN; EZN 2968; LIPOPLEX; LOCKED NUCLEIC ACID; NANOPARTICLE; POLO LIKE KINASE 1; SIG12D LODER; SMALL INTERFERING RNA; SNALP PLK1; UNCLASSIFIED DRUG;

CANCER THERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; HUMAN; LIVER CANCER; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; REVIEW; RNA INTERFERENCE; SOLID TUMOR; TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 84861584529     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.871     Document Type: Review

References (74)

1. Napoli C, Lemieux C and Jorgensen R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2: 279-289, 1990. (Pubitemid 120029588)
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998. (Pubitemid 28099681)
3. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
4. Caplen NJ, Fleenor J, Fire A and Morgan RA: dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene 252: 95-105, 2000. (Pubitemid 30618816)
5. Ui-Tei K, Zenno S, Miyata Y and Saigo K: Sensitive assay of RNA interference in Drosophila and Chinese hamster cultured cells using firefly luciferase gene as target. FEBS Lett 479: 79-82, 2000. (Pubitemid 30616410)
6. Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998. (Pubitemid 28411130)
7. Manche L, Green SR, Schmedt C and Mathews MB: Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 12: 5238-5248, 1992.
8. Minks MA, West DK, Benvin S and Baglioni C: Structural requirements of double-stranded RNA for the activation of 2',5'- oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem 254: 10180-10183, 1979.
9. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ and Kay MA: RNA interference in adult mice. Nature 418: 38-39, 2002. (Pubitemid 34742563)
10. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA and Herweijer H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32: 107-108, 2002. (Pubitemid 34977204)
11. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P and Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351, 2003. (Pubitemid 36362792)
12. Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ and Behlke MA: Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 33: 4140-4156, 2005. (Pubitemid 41487274)
13. Tuschl T, Zamore PD, Lehmann R, Bartel DP and Sharp PA: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13: 3191-3197, 1999. (Pubitemid 30030441)
14. Zamore PD, Tuschl T, Sharp PA and Bartel DP: RNAi: doublestranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33, 2000.
15. Hutvagner G: Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett 579: 5850-5857, 2005.
16. Rand T, Petersen S, Du F and Wang T: Argonaute 2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123: 621-629, 2005. (Pubitemid 41608465)
17. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L and Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437-1441, 2004. (Pubitemid 39167657)
18. Song JJ, Smith SK, Hannon GJ and Joshua-Tor L: Crystal structure of argonaute and its implications for RISC slicer activity. Science 305: 1434-1437, 2004. (Pubitemid 39167656)
19. Martinez J and Tuschl T: RISC is a 5-phosphomonoester-producing RNA endonuclease. Genes Dev 18: 975-980, 2004.
20. 2+-dependent endonuclease. Curr Biol 14: 787-791, 2004.
21. Hutvágner G and Zamore PD: A microRNA in a multipleturnover RNAi enzyme complex. Science 297: 2056-2060, 2002.
22. Dykxhoorn DM and Lieberman J: Knocking down disease with siRNAs. Cell 126: 231-235, 2006. (Pubitemid 44092975)
23. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004. (Pubitemid 39545841)
24. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O and Galun E: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 8: 769-776, 2003. (Pubitemid 37527452)
25. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM and Davidson BL: RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820, 2004. (Pubitemid 39070854)
26. Diaz-Hernandez M, Torres-Peraza J, Salvatori-Abarca A, Moran MA, Gomez-Ramos P, Alberch J and Lucas JJ: Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 25: 9773-9781, 2005. (Pubitemid 41510917)
27. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K and MacLachlan I: Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673, 2009.
28. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, Löffler K, Fechtner M, Röhl T, Fisch G, et al: RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 13: 1360-1370, 2006. (Pubitemid 44323692)
29. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918, 2005. (Pubitemid 41060730)
30. Grünweller A and Hartmann RK: RNA interference as a genespecific approach for molecular medicine. Curr Med Chem 12: 3143-3161, 2005. (Pubitemid 41749256)
31. Whitehead KA, Langer R and Anderson DG: Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138, 2009.
32. Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, Sepp-Lorenzino L and Lobell RB: Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8: 49-59, 2005. (Pubitemid 40991814)
33. Liu X and Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789-5794, 2003. (Pubitemid 36576886)
34. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel S, Czubayko F and Aigner A: RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17: 751-766, 2006. (Pubitemid 44100720)
35. Leenders F, Möpert K, Schmiedeknecht A, Santel A, Czauderna F, Aleku M, Penschuck S, Dames S, Sternberger M, Röhl T, et al: PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 23: 3303-3313, 2004. (Pubitemid 39209154)
36. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, et al: Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798, 2008.
37. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1071, 2010.
38. Li YC, Kong LH, Cheng BZ and Li KS: Construction of influenza virus siRNA expression vectors and their inhibitory effects on multiplication of influenza virus. Avian Dis 49: 562-573, 2005.
39. Thanik VD, Greives MR, Lerman OZ, Seiser N, Dec W, Chang CC, Warren SM, Levine JP and Saadeh PB: Topical matrix-based siRNA silences local gene expression in a murine wound model. Gene Ther 14: 1305-1308, 2007. (Pubitemid 47299955)
40. Peer D, Park EJ, Morishita Y, Carman CV and Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319: 627-630, 2008. (Pubitemid 351197066)
41. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ and Davis ME: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104: 5715-5721, 2007. (Pubitemid 47175600)
42. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV and Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149, 2004.
43. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK and Meyers R: Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77: 225-231, 2008.
44. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, et al: Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104: 17204-17209, 2007. (Pubitemid 350211015)
45. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, et al: Suppression of ocular neo-vascularization with siRNA targeting VEGF receptor 1. Gene Ther 13: 225-234, 2006. (Pubitemid 43148645)
46. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, deFougerolles T and Maraganore J: A status report on RNAi therapeutics. Silence 1: 1-13, 2010.
47. Castanotto D and Rossi JJ: The promises and pitfalls of RNA interference-based therapeutics. Nature 457: 426-433, 2009.
48. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA and Corey DR: RNA interference in mammalian cells by chemicallymodified RNA. Biochemistry 42: 7967-7975, 2003. (Pubitemid 36807714)
49. Chiu Y and Rana T: siRNA function in RNAi: a chemical modi- fication analysis. RNA 9: 1034-1048, 2003. (Pubitemid 37093614)
50. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA and Sullenger BA: In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771, 2004. (Pubitemid 38529739)
51. Cheng K, Ye Z, Guntaka RV and Mahato RI: Enhanced hepatic uptake and bioactivity of type a1(I) collagen gene promoterspecific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805, 2006.
52. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, et al: RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114, 2006.
53. Guo P, Coban O, Snead N, Trebley J, Hoeprich S, Guo S and Shu Y: Engineering RNA for targeted siRNA delivery and medical application. Drug Deliv Rev 62: 650-666, 2010.
54. Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007.
55. De Paula D, Bentley MV and Mahato RI: Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-450, 2007.
56. Wu Y, Wang W, Chen Y, Huang K, Shuai X, Chen Q, Li X and Lian G: The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomed 5: 129-136, 2010.
57. Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Kim JH, Nishimura S, Fujiu K, Oishi Y, Itaka K, et al: A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 69: 6531-6538, 2009.
58. Kim SH, Jeong JH, Lee SH, Kim SW and Park TG: PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116: 123-129, 2006. (Pubitemid 44854271)
59. Jain KK: The role of nanobiotechnology in drug discovery. Drug Discov Today 10: 1435-1442, 2005.
60. Gao H, Shi W and Freund LB: Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci USA 102: 9469-9474, 2005. (Pubitemid 40981705)
61. Song E, Zhu P, Lee SK, Chowdhurym D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717, 2005. (Pubitemid 41716361)
62. Nimjee SM, Rusconi CP and Sullenger BA: Aptamers: an emerging class of therapeutics. Annu Rev Med 56: 555-583, 2005. (Pubitemid 40299797)
63. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO and Giangrande PH: Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMAexpressing tumors. Nat Biotechnol 27: 839-849, 2009.
64. McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA and Giangrande PH: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015, 2006. (Pubitemid 44215395)
65. Li SD, Chen YC, Hackett MJ and Huang L: Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16: 163-169, 2008.
66. Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC and Simoes S: Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21: 157-168, 2010.
67. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME and Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992, 2005. (Pubitemid 41377390)
68. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637, 2003. (Pubitemid 36638089)
69. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN and Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100: 6347-6352, 2003. (Pubitemid 36666584)
70. Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213, 2002. (Pubitemid 34969582)
71. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, et al: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270, 2005. (Pubitemid 40460553)
72. Karikó K, Bhuyan P, Capodici J, Ni H, Lubinski J, Friedman H and Weissman D: Exogenous siRNA mediates sequence independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs 177: 132-138, 2004. (Pubitemid 39279469)
73. Judge AD, Sood V, Shaw JR, Fang D, McClintock K and MacLachlan I: Sequence dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462, 2005. (Pubitemid 41724921)
74. Singh D, Kashyap A, Pandey RV and Saini KS: Novel advances in cytochrome P450 research. Drug Discov Today 16: 793-799, 2011.